Cellular strategies to induce immune tolerance after liver transplantation:Clinical perspectives

作     者：Ai-Wei Zhou Jing Jin Yuan Liu 

作者机构：Department of Liver SurgeryRenji Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200127China Department of NursingRenji Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200127China Department of Liver TransplantationShanghai Immune Therapy InstituteShanghai 200127China 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2024年第30卷第13期

页      面：1791-1800页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：Supported by the National Natural Science Foundation of China,No.82000586 and No.82241221 and Shanghai Immune Therapy Institute. 

主　　题：Cellular therapy Induced tolerance Liver transplantation Regulatory T cells Regulatory dendritic cells 

摘      要：Liver transplantation(LT)has become the most efficient treatment for pediatric and adult end-stage liver disease and the survival time after transplantation is becoming longer due to the development of surgical techniques and perioperative management.However,long-term side-effects of immunosuppressants,like infection,metabolic disorders and malignant tumor are gaining more attention.Immune tolerance is the status in which LT recipients no longer need to take any immunosuppressants,but the liver function and intrahepatic histology maintain normal.The approaches to achieve immune tolerance after transplantation include spontaneous,operational and induced tolerance.The first two means require no specific intervention but withdrawing immunosuppressant gradually during follow-up.No clinical factors or biomarkers so far could accurately predict who are suitable for immunosuppressant withdraw after transplantation.With the understanding to the underlying mechanisms of immune tolerance,many strategies have been developed to induce tolerance in LT recipients.Cellular strategy is one of the most promising methods for immune tolerance induction,including chimerism induced by hematopoietic stem cells and adoptive transfer of regulatory immune cells.The safety and efficacy of various cell products have been evaluated by prospective preclinical and clinical trials,while obstacles still exist before translating into clinical practice.Here,we will summarize the latest perspectives and concerns on the clinical application of cellular strategies in LT recipients.